Symbols

DNA

Ginkgo Bioworks·NYSE

--(--)

DNA fundamentals

DNA Q4 2025 Earnings

Ginkgo Bioworks (DNA) released its earnings on Feb 26, 2026: revenue was 33.00M (YoY -24.74%), missed estimates; EPS was -1.41 (YoY +29.50%), beat estimates.

Revenue / YoY

33.00M

-24.74%

EPS / YoY

-1.41

+29.50%

Report date

Feb 26, 2026

DNA Earnings Call Summary for Q4,2025

Autonomous Lab Expansion: 2026 focus on scaling to 100 racks, with $47M DOE deal and cloud lab services driving growth.
Cost Efficiency: Cash burn reduced 55% to $171M in FY25, 2026 guidance of $125M-$150M reflects disciplined investment.
AI Integration Success: OpenAI collaboration achieved 40% better results, showcasing AI-driven lab automation potential.
Biosecurity Spin-Off: Divestiture enables focus on core autonomous lab strategy while retaining upside through minority stake.
Manufacturing Tailwinds: Interest in QC automation in pharma manufacturing, aligning with U.S. onshoring trends.

Earnings

EPS

Revenue

Revenue & Expenses

DNA has released its 2025 Q4 earnings report, with revenue of 33.40M, reflecting a YoY change of -23.84%, and net profit of -80.75M, showing a YoY change of 24.91%. The Sankey diagram below clearly presents DNA's revenue sources and cost distribution.

Key Indicators

Ginkgo Bioworks (DNA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ginkgo Bioworks (DNA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ginkgo Bioworks (DNA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ginkgo Bioworks (DNA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown